The core challenge in AML therapy lies in the cancer cells’ capacity to evade programmed cell death, or apoptosis, a process that is tightly regulated by a family of proteins known as BCL-2. In normal physiology, BCL-2 family proteins orchestrate the intrinsic apoptotic pathway, balancing pro-apoptotic and anti-apoptotic signals to maintain cellular homeostasis. Leukemic cells subvert this system by overexpressing pro-survival BCL-2 proteins, thereby evading chemotherapy-induced apoptosis and perpetuating malignancy. BH3 mimetics act by simulating the BH3 domain—a critical pro-apoptotic motif—enabling these compounds to selectively inhibit anti-apoptotic BCL-2 family proteins and restore apoptosis in malignant cells.

Among BH3 mimetics, venetoclax has emerged as the most clinically successful agent. This selective BCL-2 inhibitor has demonstrated remarkable efficacy in clinical trials, especially when combined with hypomethylating agents or low-dose cytarabine. These combinations have been shown to significantly enhance remission rates and prolong survival in AML patients, particularly in older individuals or those unfit for intensive chemotherapy—a patient population historically lacking viable therapeutic options. The US Food and Drug Administration (FDA) has accordingly approved these regimens, marking a pivotal advancement in AML management.

Assistant Professor Alan Prem Kumar, a leading voice in pharmacology at NUS Medicine, co-led the review alongside Assistant Professor Courtney DiNardo from the University of Texas MD Anderson Cancer Center. Reflecting on the clinical impact, Asst Prof Kumar emphasizes that venetoclax has “transformed the treatment landscape” by providing first-time access to effective therapy for frail AML patients. This breakthrough represents a paradigm shift away from the traditional, often intolerable chemotherapy regimens towards more targeted, tolerable interventions.

The review, published in Nature Reviews Clinical Oncology, synthesizes findings from over a thousand peer-reviewed articles, with a detailed focus on 236 rigorously selected studies. This exhaustive assessment maps the molecular underpinnings of BH3 mimetic function, elucidates mechanisms of drug resistance, evaluates clinical outcomes, and explores technological advances such as BH3 profiling and mitochondrial profiling. These profiling techniques allow for precise identification of the apoptotic dependencies of individual AML cells, enabling clinicians to predict drug sensitivity and tailor therapies accordingly.

Crucially, BH3 mimetics have demonstrated the ability not only to target proliferating leukemic cells but also to eradicate quiescent, non-dividing populations harboring complex genetic aberrations. This capability is significant as these dormant cells often contribute to relapse and disease persistence. However, while venetoclax heralds an era of improved outcomes, resistance remains a formidable obstacle. AML cells frequently adapt by shifting survival reliance to alternate anti-apoptotic proteins such as MCL-1 or BCL-xL, or by acquiring mutations in adverse prognostic genes including TP53, KRAS, and FLT3.

Donavan Jia Jie Tan, a first-year medical student and study co-author, underscores this therapeutic challenge, noting that cancer cells’ adaptability forces continuous innovation in treatment strategies. By integrating multiple targeted agents, combination regimens, or advanced drug delivery technologies that concurrently disrupt diverse anti-apoptotic pathways, researchers hope to mitigate resistance and enhance the durability of remissions.

This personalized treatment approach is further bolstered by the advent of BH3 and mitochondrial profiling, which Dr Lam Hiu Yan highlights as powerful tools for aligning therapeutic strategy with tumour biology. These methods facilitate the identification of patients most likely to benefit from venetoclax versus those who may require alternative BH3 mimetics targeting MCL-1 or BCL-xL, thus refining clinical decision-making and minimizing unwarranted toxicity.

Looking ahead, Asst Prof Kumar posits that the future of AML therapy hinges on the precision personalization of treatment regimens. Moving beyond a one-size-fits-all paradigm, tailoring interventions to the molecular and cellular characteristics of each patient’s leukemia will optimize efficacy and improve quality of life. This bespoke therapeutic model signals a shift towards more intelligent, biology-driven oncology care.

Independent expert Professor Chng Wee Joo of NUS Medicine, unaffiliated with the study, affirms the transformative impact of venetoclax-based therapies, especially in older adults and medically complex patients. He highlights the dramatic improvements in remission and survival that would have been unimaginable merely a decade ago. Prof Chng identifies next steps in research aimed at enhancing treatment precision, broadening accessibility, and ultimately converting AML from a once invariably fatal disease to a manageable chronic condition.

Current clinical trials are actively examining venetoclax in combination with groundbreaking agents including FLT3 inhibitors and CD47-targeting antibodies, expanding the scope of effective treatment to a wider cohort of AML patients. Parallel development pipelines are pursuing BH3 mimetics directed against MCL-1 and BCL-xL, leveraging advances in medicinal chemistry and structural biology to create novel inhibitors with improved selectivity and potency.

Taken together, this landmark review from NUS Medicine not only encapsulates the profound clinical advances ushered in by BH3 mimetics in AML but also delineates critical scientific and therapeutic challenges ahead. Through multi-disciplinary collaboration and continued innovation, researchers are poised to extend the benefits of these promising agents, paving the way for a new era where acute myeloid leukaemia becomes a disease defined not by its lethality but by the hope of durable remission and long-term survival.

Subject of Research: Acute Myeloid Leukaemia treatment using BH3 mimetics
Article Title: Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia
News Publication Date: 1-Sep-2025
Web References: https://www.nature.com/articles/s41571-025-01068-0
References: DOI 10.1038/s41571-025-01068-0
Image Credits: NUS Medicine
Keywords: Leukemia, Cancer, Myeloid leukemia, Oncology, Tumor regression, Tumor growth, Cancer risk, Blood cancer, Cell apoptosis

One of the forefront studies focuses on the unique population of adolescent and young adult (AYA) cancer survivors, individuals diagnosed between the ages of 18 and 39. This group has experienced rising cancer incidence rates over the past decade, yet their long-term health trajectories remain poorly understood. Led by oncologist and research scientist Alique Topalian, PhD, the investigation analyzes the baseline characteristics of AYA survivors receiving care in one of the nation’s few oncology primary care clinics specifically designed for cancer survivors. Utilizing a prospective clinical registry aimed at capturing longitudinal health outcomes, the team discovered that roughly 10% of the clinic’s patients were diagnosed during the AYA window.

Strikingly, 14% of these YAs had developed a second primary malignancy, underscoring an alarming predisposition for subsequent cancers in this demographic. Furthermore, cardiovascular diseases, particularly hypertension, affected about 60% of these patients, accompanied by frequent neurological, endocrine, and psychological comorbidities. Compounding these risks, lifestyle factors such as overweight and obesity prevailed in over half of the patients, with smoking histories—both former and current—adding to their vulnerability. Screening adherence varied, with breast cancer screening rates at 82%, colon cancer at 60%, and cervical cancer trailing at 40%. Topalian emphasizes the critical role oncology primary care providers must play in delivering comprehensive, lifelong monitoring and tailored preventative care to address the complex interplay of late effects and chronic conditions in this high-risk population.

Moving to hematologic malignancies, a separate investigation led by Eric Vick, MD, PhD, aims to quantify and characterize the overexpression of a protein isoform known as IRAK4L in acute myeloid leukemia (AML). Prior studies had recognized IRAK4L as hyperactive in AML cells, but precise expression levels and implications for chemotherapeutic resistance had remained elusive. By assessing animal models and patient-derived AML cell lines, Vick’s group demonstrated that most AML cancer cells express predominantly the IRAK4L isoform. When treated with azacitidine, a hypomethylating agent, and venetoclax, a targeted BCL-2 inhibitor, transient suppression of IRAK4L expression was observed. However, post-treatment recovery led to restoration of baseline protein levels, indicating that existing therapies only temporarily modulate this pro-tumorigenic pathway.

The implications of these findings extend to the development of next-generation pharmacologic inhibitors targeting IRAK4 as part of multifaceted therapeutic regimens. Vick anticipates that novel IRAK4 inhibitors may enter clinical trials imminently, presenting opportunities to overcome AML’s notorious ability to evade current treatment modalities. This research exemplifies the strategic shift toward precision medicine guided by molecular vulnerabilities inherent to specific leukemic subtypes.

Immunotherapy remains a dynamic frontier in oncology, highlighted by investigation into oncolytic viral therapies. The Phase 2 IGNYTE trial explores RP1, a genetically modified herpes simplex virus type 1 engineered to selectively infect and lyse tumor cells while stimulating systemic antitumor immunity. Under the guidance of Trisha Wise-Draper, MD, PhD, biosafety analyses of RP1’s behavior in patients with skin cancers revealed minimal viral dissemination beyond tumor sites. Detection of viral particles in blood, urine, and patient surfaces was negligible, with no secondary infections reported among close contacts or family members.

These safety data affirm that RP1’s replication remains tumor-restricted, a critical property to mitigate risks of contagion and systemic viral illness. Wise-Draper highlights that such reassuring biosafety profiles are essential for the continued evaluation of oncolytic viruses as viable immunotherapeutic agents. The ongoing trial aims to balance potent oncolytic activity with rigorous safety standards, setting the stage for broader incorporation of engineered viral platforms in oncology.

Another compelling study addresses the therapeutic void in adenoid cystic carcinoma (ACC), a rare, indolent yet treatment-resistant head and neck malignancy. Researchers under the mentorship of Wise-Draper initiated a Phase 2 clinical trial assessing amivantamab, a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and MET pathways. Previously approved for lung cancer-resistant variants, amivantamab was evaluated for its potential to surmount ACC’s notorious drug resistance. Among the 21 enrolled patients, partial tumor responses were noted, with one case achieving a 30% reduction in lesion size. Additionally, 10 patients demonstrated stable disease, culminating in a clinical benefit rate of 61%.

Importantly, the therapeutic regimen was well tolerated, with side effects confined primarily to manageable infusion reactions and skin rashes. Patient-reported quality of life remained stable throughout treatment. Researchers plan to conduct extensive molecular profiling of tumor specimens to identify predictive biomarkers that may refine patient selection and optimize therapeutic efficacy. This work lays the foundation for future amivantamab combination trials or expanded enrollment to validate its role in ACC management.

In a groundbreaking advancement for rare pediatric and young adult kidney cancers, James I. Geller, MD, reports findings from the national Phase 2 AREN1721 trial targeting translocation renal cell carcinoma (tRCC). This aggressive neoplasm is driven by chromosomal rearrangements involving TFE3 or TFEB transcription factors, resulting in aberrant gene expression and unchecked tumor growth. The trial evaluated a novel combination therapy pairing nivolumab, an immune checkpoint inhibitor that invigorates antitumor T-cell responses, with axitinib, a tyrosine kinase inhibitor that disrupts tumor angiogenesis.

Though the study enrolled just 13 patients aged 7 to 42, outcomes were promising. The dual therapy extended median progression-free survival to 10.5 months, markedly outperforming nivolumab monotherapy, which yielded a median progression of 1.8 months. Approximately one-third of combination recipients experienced partial tumor regression, a feat not observed with single-agent immunotherapy. Adverse event profiles were consistent with known drug toxicities and presented no unexpected safety concerns. Geller underscores the significance of these results, signaling a pivotal step toward improved treatment paradigms for tRCC, although he stresses the necessity for continued clinical innovation.

Collectively, these diverse research initiatives highlight the University of Cincinnati Cancer Center’s commitment to advancing oncologic knowledge across age groups, cancer types, and therapeutic modalities. From elucidating the complex long-term health needs of AYA cancer survivors to pioneering molecularly guided treatments in intractable malignancies, the findings presented at ASCO 2025 portend a future in which personalized cancer care is not an aspiration but a standard. As cancer patients live longer and treatments evolve, multidisciplinary endeavors such as these ensure that survivorship and quality of life receive as much attention as disease eradication.

Emerging themes across these studies include the urgent necessity for longitudinal monitoring of high-risk populations, interdisciplinary collaboration bridging basic science and clinical practice, and regulatory frameworks that support innovative trial designs. Moreover, advances in molecular profiling and immune oncology herald an era where therapeutic resistance can be anticipated and circumvented rather than merely managed. These strides bring hope that tomorrow’s cancer treatments will be smarter, more effective, and tailored uniquely to each patient’s biology and experience.

The spotlight on adolescent and young adult oncology exemplifies a critical recalibration in the oncology community’s approach to survivorship. Tailored prevention, comprehensive primary care, and enhanced provider-patient education form the cornerstones of this evolving paradigm. Likewise, efforts to refine immunotherapies and targeted agents shown in trials of IRAK4 inhibitors, oncolytic viruses, and antibody-drug conjugates underscore a nuanced understanding of cancer’s molecular underpinnings and immune evasion tactics.

As the ASCO Annual Meeting convenes, the collective momentum fosters optimism and underscores the vibrancy of cancer research. The University of Cincinnati Cancer Center’s multifaceted contributions, spanning from bench to bedside, reflect the broader shift in oncology toward integration, precision, and compassionate care for all patients, regardless of age, cancer type, or stage.

—

Subject of Research: Oncology research encompassing adolescent and young adult cancer survivorship, acute myeloid leukemia molecular targets, oncolytic virus safety, rare head and neck cancer therapies, and novel treatments for rare kidney cancers.

Article Title: University of Cincinnati Cancer Center Unveils Pioneering Research at ASCO 2025: Advances in AYA Survivorship, AML Molecular Targets, and Novel Cancer Therapies

News Publication Date: May 2025

Web References:
– IGNYTE trial (NCT03767348) – https://clinicaltrials.gov/study/NCT03767348

Keywords: Oncology, Adolescent and Young Adult (AYA) Survivorship, Acute Myeloid Leukemia (AML), IRAK4L Protein, Oncolytic Virus, RP1, Amivantamab, Adenoid Cystic Carcinoma (ACC), Translocation Renal Cell Carcinoma (tRCC), Immunotherapy, Targeted Therapy, Nivolumab, Axitinib

Ulrich Steidl, M.D., Ph.D., a pioneering investigator in the molecular and cellular basis of blood disorders, has been inducted into the prestigious Association of American Physicians (AAP). This venerable institution, with a legacy spanning nearly a century and a half, represents the pinnacle of physician-scientist excellence, honoring those whose research innovation profoundly advances medical science. Dr. Steidl serves as professor and chair of cell biology at the Albert Einstein College of Medicine and acts as deputy director at the Montefiore Einstein Comprehensive Cancer Center, a National Cancer Institute (NCI)-designated facility renowned for its research and clinical care.

The announcement, made on April 26, recognizes Dr. Steidl’s exemplary contributions to understanding the pathogenesis of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), two hematologic malignancies with complex stem cell origins. His election to the AAP underscores his stature as a leader synthesizing basic molecular insights with translational strategies aimed at improving patient outcomes. According to the AAP, membership is conferred upon individuals who demonstrate exceptional physician-led scientific leadership and groundbreaking research accomplishments.

At the heart of Dr. Steidl’s research lies a profound investigation into the biology of hematopoietic stem cells that give rise to MDS and ultimately AML. His work, driven by robust NIH and private funding, delves into the molecular abnormalities within pre-leukemic stem cells — the precursors to malignant clones. By elucidating the cellular pathways and genetic alterations underpinning the transition from pre-leukemic to full leukemic states, Dr. Steidl has charted pathways that are critical for early intervention and targeted therapy development. This insight is shifting paradigms in hematologic oncology, moving from symptom management to molecularly precise disruption of disease progression.

Significantly, Dr. Steidl was among the first researchers to demonstrate the defective nature of hematopoietic stem cells in MDS, a disorder recognized as a precursor to AML. This conceptual breakthrough, published in high-impact journals such as Nature Medicine, revolutionized the understanding of how these diseases originate and evolve at the stem cell level, challenging previously accepted models. Through this work, he has laid the foundation for novel therapeutic agents currently undergoing clinical trials, aiming to eradicate the aberrant stem cell populations that drive disease perpetuation and relapse.

The translational arc of Dr. Steidl’s research is underscored by his receipt of the National Cancer Institute’s Outstanding Investigator Award in 2021 — a competitive grant that supports sustained, innovative research endeavors. This award, accompanied by a seven-year funding commitment of $7 million, enables his laboratory to probe deeper into the genetic and epigenetic mechanisms governing stem cell transformation. It also facilitates the development and testing of drug candidates designed to selectively target malignant stem cells without compromising normal hematopoiesis, a critical balance in preventing treatment-related toxicity.

In addition to his laboratory investigations, Dr. Steidl holds the Edward P. Evans Endowed Professorship for Myelodysplastic Syndromes and serves as interim director of the Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine. His leadership roles emphasize his commitment to fostering interdisciplinary collaboration and advancing regenerative approaches to hematologic disease. The Gottesman Institute represents a hub where stem cell biology, molecular genetics, and translational medicine converge to create innovative therapeutic strategies.

Dr. Steidl’s work is characterized by the seamless integration of cutting-edge genomic technologies, including single-cell RNA sequencing and CRISPR-Cas9 gene editing, with classical hematology. This combination allows his team to dissect the cellular heterogeneity within MDS and AML, identifying rare populations of cells that resist conventional chemotherapy and contribute to disease relapse. These findings have profound implications for the design of next-generation therapeutics capable of achieving long-term remission or cure.

Yaron Tomer, M.D., the Marilyn and Stanley M. Katz Dean at Einstein and chief academic officer at Montefiore Einstein, lauded Dr. Steidl’s induction into the AAP as a testament to his scientific rigor and translational impact. He highlighted Dr. Steidl as a physician-scientist whose research exemplifies how mechanistic studies at the molecular level can directly inform clinical practice. This bridge between bench and bedside is essential for addressing the unmet needs of patients afflicted by aggressive hematologic cancers.

More than 150 peer-reviewed publications bear Dr. Steidl’s name, illustrating the depth and breadth of his contributions to cancer biology. His research not only advances fundamental understanding but also influences clinical protocols, as several experimental therapies originating from his findings are in human trials. These trials evaluate compounds targeting aberrant survival pathways and stem cell self-renewal mechanisms, reflecting a new era of precision medicine in blood cancers.

The Montefiore Einstein Comprehensive Cancer Center, where Dr. Steidl is a deputy director, represents a model institution that merges scientific discovery with patient-centered care. NCI-designated since 1972, the center serves one of the nation’s most diverse populations, with a deliberate focus on reducing health disparities through inclusive research and community engagement. Dr. Steidl’s appointment to this leadership cadre reinforces the center’s commitment to excellence in cancer stem cell research.

Among the distinguished cohort of previous Albert Einstein College of Medicine faculty elected to the AAP are renowned physician-scientists who have made landmark contributions across various disciplines. The induction of Dr. Steidl continues this legacy of scientific achievement and highlights the institution’s role as a breeding ground for innovation in medical research.

Dr. Steidl expressed profound gratitude for the recognition, acknowledging the collaborative environment at Einstein, the inspiration derived from patients, and the support from colleagues and trainees. His statement reflects a dedication not only to advancing scientific frontiers but also to mentoring the next generation of physician-scientists who will carry forward the torch of translational research.

In sum, Dr. Ulrich Steidl’s election to the Association of American Physicians underscores his seminal role in uncovering the molecular drivers of MDS and AML, shaping new therapeutic landscapes, and exemplifying the integration of rigorous science with compassionate clinical care. His work heralds promising directions for the treatment of complex blood malignancies, emphasizing early detection and targeted intervention at the stem cell level. As the field evolves towards more personalized and effective therapies, Dr. Steidl’s discoveries continue to illuminate the path forward.

Subject of Research: Molecular and cellular mechanisms underlying myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), with emphasis on the biology of pre-leukemic and leukemic stem cells.

Article Title: Ulrich Steidl, M.D., Ph.D., Joins Association of American Physicians for Pioneering Work in Blood Stem Cell Research

News Publication Date: April 26, 2024

Web References:

• Faculty profile: https://einsteinmed.edu/faculty/11118/ulrich-g-steidl
• Montefiore Einstein Comprehensive Cancer Center: https://montefioreeinstein.org/cancer
• Albert Einstein College of Medicine: https://einsteinmed.edu

References:

• Steidl U, et al. “Myelodysplastic syndromes arise from hematopoietic stem cells with molecular defects.” Nature Medicine. 2018. https://www.nature.com/articles/s41591-018-0267-4

Image Credits: Albert Einstein College of Medicine

Keywords: Stem cell research, Cancer research, Clinical research, Hematologic malignancies, Myelodysplastic syndromes, Acute myeloid leukemia, Translational research, NIH Outstanding Investigator Award, Molecular biology, Targeted therapy, Precision medicine